Chronic Trypanosoma cruzi infections are typically lifelong, with small numbers of parasites
surviving in restricted tissue sites, which include the gastrointestinal tract. There is …

Investigations into intracellular replication and differentiation of Trypanosoma cruzi within
the mammalian host have been restricted by limitations in our ability to detect parasitized …

Trypanosoma cruzi is the etiological agent of Chagas disease. Following T cell-mediated
suppression of acute-phase infection, this intracellular eukaryotic pathogen persists long …

Infections with Trypanosoma cruzi are usually lifelong despite generating a strong adaptive
immune response. Identifying the sites of parasite persistence is therefore crucial to …

A major contributor to treatment failure in Chagas disease, caused by infection with the
protozoan parasite Trypanosoma cruzi, is that current treatment regimens do not address the …

Benznidazole is the front-line drug used to treat infections with Trypanosoma cruzi, the
causative agent of Chagas disease. However, for reasons that are unknown, treatment …

Trypanosoma cruzi is a protozoan parasite causing Chagas disease, with a complex life
cycle involving different stages in insect vectors and mammalian hosts. Amastigotes are an …

As Trypanosoma cruzi, the etiological agent of Chagas disease, multiplies in the cytoplasm
of nucleated host cells, infection with this parasite is highly likely to affect host cells. We …

In chronic Trypanosoma cruzi infections, parasite burden is controlled by effective, but
nonsterilising immune responses. Infected cells are difficult to detect because they are …

Host and parasite diversity are suspected to be key factors in Chagas disease pathogenesis.
Experimental investigation of underlying mechanisms is hampered by a lack of tools to …